The asymptomatic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now become the focus of epidemic control in Wuhan. Patients with cancer, a large population of immunocompromised individuals, have been observed to have a higher risk of coronavirus disease 2019 (COVID-19) infection.[@bib1] However, reports on cancer patients with asymptomatic infection are still scarce.[@bib2]

A retrospective study was performed to evaluate asymptomatic infections in 5119 individuals without typical symptoms of COVID-19 infection (including 2818 patients with cancer and 2301 caregivers without cancer). These individuals received an oropharyngeal swab test for SARS-CoV-2 nucleic acid by RT-PCR and/or serum specific antibody \[immunoglobulin M (IgM) and IgG\] test from 29 March to 23 April 2020, in Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, P. R. China). The asymptomatic infections were identified by positivity to nucleic acid and/or antibodies (IgM/IgG). The incidence of infection was calculated as the proportion of infected individuals in the population.

The incidence of asymptomatic infection was 2.9% (81/2818) in patients with cancer, whereas it was 2.1% (49/2301) in their caregivers. There was no statistical difference in infection risk between patients with cancer and their caregivers \[relative risk 1.36, 95% confidence interval (CI) 0.95--1.95\]. Furthermore, positive results were not simultaneously observed in both patients and their caregivers. The close contacts and index patient were followed up for 10--32 days, and none of them developed symptoms.

We also evaluated the correlations between age, sex, or anticancer treatment, and asymptomatic infection in patients with cancer ([Table 1](#tbl1){ref-type="table"} ). All the infected patients with cancer received anticancer treatment within the past 2 months. A total of 12 patients (14.8%) were diagnosed with stage IV cancer. Breast cancer was the cancer type with the most frequent infections. Among patients with cancer, chemotherapy \[odds ratio (OR) 4.65, 95% CI 2.39--9.06\] and targeted therapy (OR 1.90, 95% CI 1.18--3.05) were the risk factors for infection.Table 1Association analyses of age, sex, anticancer treatment, and tumor diagnosis in cancer patients with asymptomatic infectionWith asymptomatic infectionWithout asymptomatic infection*P*[a](#tbl1fna){ref-type="table-fn"}OR (95% CI)Total81 (2.9)2737 (97.1)Age, mean (SD), years56.4 (10.9)54.8 (12.3)0.27--- ≥6034 (41.98)1036 (37.85)0.451.19 (0.76--1.86) \<6047 (58.02)1701 (62.15)Sex Male35 (43.2)1368 (50.0)0.230.76 (0.48--1.19) Female46 (56.8)1369 (50.0)Anticancer treatment Surgery Yes48 (59.3)1377 (50.3)0.111.44 (0.92--2.25) No33 (40.7)1360 (49.7) Radiotherapy Yes13 (16.1)309 (11.3)0.181.50 (0.82--2.75) No68 (83.9)2428 (88.7) Chemotherapy Yes71 (87.7)1832 (66.9)\<0.014.65 (2.39--9.06) No10 (12.3)905 (33.1) Target therapy Yes26 (32.1)546 (19.9)\<0.011.90 (1.18--3.05) No55 (67.9)2191 (80.1) Immunotherapy Yes4 (4.9)203 (7.4)0.400.65 (0.24--1.79) No77 (95.1)2534 (92.6)Tumor diagnosis[b](#tbl1fnb){ref-type="table-fn"} Breast cancer24 (29.6) Lung cancer16 (19.8) Liver cancer12 (14.8) Gastrointestinal cancer11 (13.6) Brain tumor3 (3.7) Endometrial cancer3 (3.7) Lymphoma3 (3.7) Cervical cancer2 (2.5) Prostatic cancer2 (2.5) Glottic cancer1 (1.2)Tumor stage[c](#tbl1fnc){ref-type="table-fn"} Stage I/II/III69 (85.2) Stage IV12 (14.8)[^2][^3][^4][^5]

It remains largely unclear how to prioritize the treatment of patients with cancer in the postpandemic period. The available evidence is limited.[@bib3] Our research originally suggested some highlights on 'truly' asymptomatic infection in patients with cancer in Wuhan, China, who were symptom free over the preceding 14 days. In our present study, patients with cancer exhibited the equivalent susceptibility of asymptomatic infection compared with their caregivers. However, these patients with cancer possess a higher risk than those without,[@bib4] suggesting that frequent exposure to SARS-CoV-2 can increase the infectious risk of patients with cancer who receive anticancer treatment, but not cancer itself. Moreover, our findings indicated feeble virulence and transmission of asymptomatic infections. Therefore, admission of cancer patients with asymptomatic infection might not trigger a nosocomial infection if the rigorous infection control and personal protection procedures are followed. We also evaluated the risk factors of the infection in patients with cancer, and our data indicated that chemotherapy and targeted therapy could increase the infectious risk. To develop a reasonable and balanced treatment strategy between cancer and infection, analyses should be performed to evaluate whether anticancer treatments might predispose patients to the more severe outcome of asymptomatic infection, particularly chemotherapy and targeted therapy.
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